10 results about "Epitope" patented technology

The present invention provides a monoclonal anti-idiotype antibody 11D10 that elicits an immune response against a specific epitope of a high molecular weight mucin of human milk fat globule (HMFG) and a hybridoma that produces 11D10. The hybridoma that produces 11D10 was selected by specific procedures. 11D10 induces an immunological response to HMFG in nice, rabbits, monkeys and patients with advanced HMFG-associated tumors. This invention provides compositions derived from polynucleotide sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 11D10, as well as polypeptides encoded thereby. The invention also provides compositions which can be used in the detection or treatment of HMFG-associated tumors.

A method for localizing and identifying specific epitopes on a molecule using electron microscopy in combination with specific labeling of the epitopes by e.g. antibodies. The electron microscopy is performed using a very low electron dose, which allows the labeling molecules to remain bound to their epitopes.

The invention discloses a preparation method and application of a fluorescent reagent strip for quantitatively detecting the concentration of ProAKAP4, and belongs to the field of in-vitro diagnostic reagents; a fluorescence immunochromatography technology is introduced into the detection of proAKAP4, and the prepared immunochromatography test strip for proAKAP4 adopts a double-antibody sandwich method; a proAKAP4 antigen in a sample pad is combined with a proAKAP4 antibody marked by fluorescent microspheres on a marking pad under the chromatographic action to form a compound, the compound moves to a detection line of a coating film under the chromatographic action, and the detection line of the coating film is coated with an antibody for identifying the other epitope of the proAKAP4 antigen to form a double-antibody sandwich compound; proAKAP4 with the concentration as low as 0.1 ng/mL in a seminal fluid sample can be detected, a detection result can be read through an immunofluorescence analyzer, professional operators are not needed, single-person quantitative detection of proAKAP4 is achieved, and the kit has the advantages of being convenient and rapid to use, easy to operate, high in sensitivity, easy to operate, low in detection cost and the like.

The present invention is directed to a recombinant immunogenic polypeptide. The polypeptide includes a loop peptide inserted into an immunogenic scaffold protein. The loop polypeptide has an amino acid sequence which presents the 3074 mAb- or the 2219/2557 mAb-targeted epitope of the HIV gp120 protein and not other known epitopes of the HIV gp120 protein. When used as an immunogen, the polypeptide induces an antibody response which neutralizes heterologous HIV-1 viruses in a pattern similar to that observed for the 3074 mAb- or the 2219/2557 mAb-targeted epitope, respectively. Pharmaceutical compositions containing the immunogenic polypeptide as well as methods of making and using it are also disclosed.

Vaccine compositions and methods are described for providing immunity to porcine circovirus type two (PCV2) genotypes including by administration of a recombinant PCV2 capsid polypeptide which comprises antigenic epitopes from the capsids of multiple PCV2 genotypes. In other embodiments a recombinant chimeric porcine circovirus is provides for use as a vaccine that combines the nonpathogenic backbone of porcine circovirus type 1 (PCV1) with the sequences encoding a PCV2 capsid polypeptide comprises antigenic epitopes from the capsids of multiple PCV2 genotypes.

The present disclosure describes peptide inhibitors of Rho-associtated-kinase (ROCK) and their use in treating disorders including heart failure, the leading cause of combined morbidity and mortality in the United States. An inhibitory polypeptide blocks ROCK1 activity in the presence of 1 mM ATP. The binding epitope on ROCK1 was mapped using chemical cross-linking to the Activation Loop, a novel locus identifying a new class of inhibitory drugs. The peptides described will be useful against a number of important diseases such as heart disease, pulmonary hypertension, arterial hypertension, gluacoma management, insulin resistance, kidney disease, hemolytic anemia, stroke, ischemia reperfusion injury, or acute mycloid leukemia.